fasudil has been researched along with Pulmonary Arterial Hypertension in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Pulmonary Arterial Hypertension: A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Given the therapeutic efficacy of fasudil hydrochloride (F) and dichloroacetate (DCA) on pulmonary arterial hypertension (PAH), a new salt fasudil dichloroacetate (FDCA) was designed, synthesized and biologically evaluated." | 7.91 | Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats. ( Cheng, Y; Han, H; Huang, Z; Kong, H; Lv, T; Qi, L; Wang, H; Xie, W; Yu, M; Zhang, Y, 2019) |
| " Considering increased ROCK activity contribution to progression of PAH, ROCK inhibition influences NO bioavailability through RBC eNOS, in addition to endothelial eNOS." | 5.56 | Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil. ( Basarici, I; Basrali, F; Celik, ML; Kilavuz, E; Kısak, F; Koksoy, S; Özen, N; Ulker, P; Yaras, N, 2020) |
| "Given the therapeutic efficacy of fasudil hydrochloride (F) and dichloroacetate (DCA) on pulmonary arterial hypertension (PAH), a new salt fasudil dichloroacetate (FDCA) was designed, synthesized and biologically evaluated." | 3.91 | Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats. ( Cheng, Y; Han, H; Huang, Z; Kong, H; Lv, T; Qi, L; Wang, H; Xie, W; Yu, M; Zhang, Y, 2019) |
| " Considering increased ROCK activity contribution to progression of PAH, ROCK inhibition influences NO bioavailability through RBC eNOS, in addition to endothelial eNOS." | 1.56 | Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil. ( Basarici, I; Basrali, F; Celik, ML; Kilavuz, E; Kısak, F; Koksoy, S; Özen, N; Ulker, P; Yaras, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, K | 1 |
| Akagi, S | 1 |
| Ejiri, K | 1 |
| Yoshida, M | 1 |
| Miyoshi, T | 1 |
| Toh, N | 1 |
| Nakagawa, K | 1 |
| Takaya, Y | 1 |
| Matsubara, H | 1 |
| Ito, H | 1 |
| Basarici, I | 1 |
| Özen, N | 1 |
| Kilavuz, E | 1 |
| Kısak, F | 1 |
| Basrali, F | 1 |
| Yaras, N | 1 |
| Koksoy, S | 1 |
| Celik, ML | 1 |
| Ulker, P | 1 |
| Qi, L | 1 |
| Lv, T | 1 |
| Cheng, Y | 1 |
| Yu, M | 1 |
| Han, H | 1 |
| Kong, H | 1 |
| Xie, W | 1 |
| Wang, H | 1 |
| Zhang, Y | 1 |
| Huang, Z | 1 |
1 review available for fasudil and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5 | 2019 |
2 other studies available for fasudil and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: Decreased red blood cell nitric oxide generation and effect of Rho-Kinase inhibitor fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Case-Control Studies; Erythrocytes; Female; Hu | 2020 |
Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Male; Protein Kinase I | 2019 |